Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse
- 24 February 2006
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 24 (6) , 459-464
- https://doi.org/10.1007/s10637-006-5947-0
Abstract
DMU-135 (3,4-Methylenedioxy-3′,4′,5′-trimethoxy chalcone) is a novel anticancer prodrug designed to be activated into a potent tyrosine kinase inhibitor by the tumour selective enzyme activity of the cytochrome P450 enzyme CYP1B1. CYP1B1 is selectively expressed in a wide variety of tumours including colon. The hypothesis was tested that DMU-135 would inhibit ApcMin/+ mouse gastrointestinal adenoma formation. From 4–18 weeks of age animals received DMU-135 (0.2% w:w) in AIN93G diet. DMU-135 was well tolerated, induced no systemic side-effects and reduced adenoma multiplicity by 46 ± 18.3% compared to controls (p < 0.001). Further characterisation of this promising chemopreventive agent is required.Keywords
This publication has 24 references indexed in Scilit:
- Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4′‐tetramethoxystilbene (DMU‐212) on adenoma development in the ApcMin+ mouse and cyclooxygenase‐2 in human‐derived colon cancer cellsInternational Journal of Cancer, 2005
- Vioxx risk could signify trouble in classNature Reviews Drug Discovery, 2004
- Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phaseCancer, 2004
- A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patientsThe Esophagus, 2004
- Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system.2003
- Age-related difference in susceptibility of ApcMin/+ mice towards the chemopreventive efficacy of dietary aspirin and curcuminBritish Journal of Cancer, 2003
- Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.2002
- Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesisProceedings of the National Academy of Sciences, 2002
- Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation.1999
- Loss of Apc+ in intestinal adenomas from Min mice.1994